Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Prof Paolo A Ascierto, Daniil Stroyakovskiy, Prof Helen Gogas,Prof Caroline Robert, Prof Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Natalia Zhukova, Prof Jacob Schachter,Yibing Yan, Ivor Caro, Christian Hertig, Cloris Xue, Lieke Kusters, Prof Grant A McArthur, Prof Ralf Gutzmer

The Lancet Oncology, Novembrer 29, 2022

Abstract link